


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A tetrahydroquinoline derivative according to Formula 1,



Formula I

or a pharmaceutically acceptable salt thereof, wherein

R¹ and R² are H or Me

R³ is H, hydroxy, (1-4C)alkoxy, (di)(1-4C)alkylamino(2-4C)alkoxy or (2-6)heterocycloalkyl(2-4C)alkoxy

R⁴ is H, OH, or (1-4C)alkoxy or R⁷

R⁵ is H, OH, (1-4C)alkoxy or R⁷

with the proviso that if R⁴ is H, R⁵ is not H, OH or (1-4C)alkoxy and that if R⁵ is H, R⁴ is not H, OH or (1-4C)alkoxy

R⁶ is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, (2-6C)heterocycloalkyl or (1-6C)alkyl, wherein the (2-5C)heteroaryl and the (6C)aryl are optionally substituted with one or more substituents selected from hydroxyl, amino, halogen, nitro, phenyl, (1-4C)alkyl, (1-4C)alkoxy, or (1-4C)(di)alkylamino

R⁷ is amino, (di)(1-4C)alkylamino, ~~(6C)arylecarbonylamino~~,
~~(6C)arylecarbonyloxy~~, (2-5C)heteroarylcarbonylamino, (2-5C)heteroarylcarbonyloxy, R⁸-
~~(2-4C)alkylamino~~, R⁸-(2-4C)alkoxy, R⁹-methylamino or R⁹-methoxy
R⁸ is hydroxy, amino, (1-4C)alkoxy, (di)(1-4C)alkylamino, (2-
6C)heterocycloalkyl, (2-6C)heterocycloalkylcarbonylamino, ~~(di)(1-~~
~~4C)alkylaminocarbonylamino~~, or (1-4C)alkoxycarbonylamino and
R⁹ is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (2-5C)heteroaryl,
optionally substituted with one or more (1-4C)alkyl substituents, or (6C)aryl.

2. (Cancelled).
3. (Cancelled).
4. (Currently Amended) The tetrahydroquinoline derivative of claim 3 1 wherein R⁸ is amino, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl or (2-6C)heterocycloalkylcarbonylamino.
5. (Currently Amended) The tetrahydroquinoline derivative of claim 2 1 wherein R⁷ is (di)(1-4C)alkylamino, R⁸-(2-4C)alkoxy, R⁹-methylamino or R⁹-methoxy.
6. (Previously presented) The tetrahydroquinoline derivative of claim 5 wherein R⁸ is amino, (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
7. (Previously presented) The tetrahydroquinoline derivative of claim 6 wherein R⁸ is (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
8. (Cancelled).
9. (Currently Amended) The tetrahydroquinoline derivative of claim 8 5 wherein R⁶ is (2-5C)heteroaryl or (6C)aryl.

10. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R⁶ is (4-5C)heteroaryl or (6C)aryl and R9 is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.
11. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R⁷ is (di)(1-4C)alkylamino, R⁸-ethoxy, R⁹-methylamino or R⁹-methoxy and R⁹ is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.
12. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R⁸ is (di)(1-4C)alkylamino or (4-5C)heterocycloalkyl and R⁹ is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.
13. (Previously presented) A pharmaceutical composition comprising the tetrahydroquinoline derivative of claim 1 and at least one pharmaceutically suitable auxiliary.
14. (Cancelled)
15. (Cancelled)
16. (Previously presented) A method of fertility regulation comprising administering an FSH receptor activity modulating amount of the pharmaceutical composition of claim 13.